Compare Stocks: FGEN, HCM, and MRTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FGEN FibroGen	$9.77 +8.3%	$9.21	$4.85 ▼ $12.60	$39.57M	0.77	40,794 shs	31,125 shs
HCM HUTCHMED	$13.57 -2.2%	$11.95	$9.77 ▼ $18.30	$2.42B	0.24	99,561 shs	95,015 shs
MRTX Mirati Therapeutics	$58.70	$58.82	$27.30 ▼ $64.41	$4.12B	0.77	2.76 million shs	N/A

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FGEN FibroGen	0.00%	0.00%	0.00%	0.00%	-14.90%
HCM HUTCHMED	-2.23%	+12.71%	+8.13%	+26.76%	-15.45%
MRTX Mirati Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FGEN FibroGen	$9.77 +8.3%	$9.21	$4.85 ▼ $12.60	$39.57M	0.77	40,794 shs	31,125 shs
HCM HUTCHMED	$13.57 -2.2%	$11.95	$9.77 ▼ $18.30	$2.42B	0.24	99,561 shs	95,015 shs
MRTX Mirati Therapeutics	$58.70	$58.82	$27.30 ▼ $64.41	$4.12B	0.77	2.76 million shs	N/A

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FGEN FibroGen	0.00%	0.00%	0.00%	0.00%	-14.90%
HCM HUTCHMED	-2.23%	+12.71%	+8.13%	+26.76%	-15.45%
MRTX Mirati Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FGEN FibroGen	2.00	Hold	$43.00	340.12% Upside
HCM HUTCHMED	2.43	Hold	$14.87	9.56% Upside
MRTX Mirati Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest FGEN, HCM, and MRTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/8/2026	HCM HUTCHMED	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy
9/3/2026	HCM HUTCHMED	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy
7/31/2026	HCM HUTCHMED	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)
7/23/2026	HCM HUTCHMED	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$16.00 ➝ $14.00
7/17/2026	HCM HUTCHMED	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
7/7/2026	HCM HUTCHMED	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$20.00 ➝ $17.00
6/29/2026	HCM HUTCHMED	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FGEN FibroGen	$29.62M	1.34	N/A	N/A	($50.89) per share	-0.19
HCM HUTCHMED	$548.51M	4.32	$2.63 per share	5.15	$7.17 per share	1.89
MRTX Mirati Therapeutics	$12.44M	331.01	N/A	N/A	$17.31 per share	3.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FGEN FibroGen	-$47.58M	$53.48	0.18	N/A	N/A	2,598.55%	N/A	-26.27%	N/A
HCM HUTCHMED	$456.91M	N/A	N/A	61.68	N/A	N/A	N/A	N/A	N/A
MRTX Mirati Therapeutics	-$740.87M	-$12.22	N/A	N/A	N/A	-1,900.65%	-82.15%	-67.82%	N/A

Latest FGEN, HCM, and MRTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
7/30/2026	H1 2026	HCM HUTCHMED	$0.1450	$0.05	-$0.0950	$0.05	$304.16 million	$139.14 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FGEN FibroGen	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
MRTX Mirati Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FGEN FibroGen	N/A	3.71	3.60
HCM HUTCHMED	0.06	5.64	5.50
MRTX Mirati Therapeutics	N/A	7.54	7.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FGEN FibroGen	72.71%
HCM HUTCHMED	8.82%
MRTX Mirati Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
FGEN FibroGen	3.07%
HCM HUTCHMED	3.60%
MRTX Mirati Therapeutics	3.26%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FGEN FibroGen	570	4.05 million	3.92 million	Optionable
HCM HUTCHMED	1,796	174.47 million	168.19 million	Not Optionable
MRTX Mirati Therapeutics	587	70.15 million	67.86 million	No Data

FGEN, HCM, and MRTX Headlines

Recent News About These Companies

BMS removes 2 clinical programs from pipeline, one from Mirati and another from Exscientia

October 31, 2025 | fiercebiotech.comF

Mirati's Flagship Drug Faces Mounting Pressure from Lilly's New Therapy

September 4, 2025 | aktiencheck.deA

Mirati Therapeutics Stock Price History

May 26, 2025 | investing.com

New GTPase KRAS mutant inhibitors disclosed in Mirati patent

December 12, 2024 | bioworld.comB

Mirati Therapeutics Receives Untitled Letter from OPDP for Overstating Cancer Drug Efficacy

October 15, 2024 | policymed.comP

Pharma M&A rumour mill grinds out Mirati's name again

August 16, 2024 | pharmaphorum.comP

Mirati's Charles Baum takes the helm at Terremoto Biosciences

July 25, 2024 | fiercebiotech.comF

Mirati Therapeutics gets grant for combination therapy for treating kras G12C cancers

April 17, 2024 | pharmaceutical-technology.comP

Mirati Therapeutics gets grant for combination therapy for treating kras G12C cancers

April 17, 2024 | pharmaceutical-technology.comP

How this insider trader nailed every single stock trade

April 5, 2024 | finbold.comF

The workforce reduction at Mirati Therapeutics will take place over the next year and impacts more than 400 employees.

April 3, 2024 | sandiegouniontribune.comS

Mirati Therapeutics files patent for inhibitors of KRAS g12d

March 26, 2024 | pharmaceutical-technology.comP

Bristol Myers Squibb cuts hundreds of Mirati staffers months after closing $5.8B buyout

March 26, 2024 | fiercepharma.comF

Bristol Myers Squibb concludes acquisition of Mirati Therapeutics

January 26, 2024 | medicaldialogues.inM

Bristol Myers Squibb completes acquisition of Mirati Therapeutics

January 25, 2024 | pharmabiz.comP

Mirati Therapeutics Receives Marketing Authorization For KRAZATI From European Commission

January 10, 2024 | markets.businessinsider.com

European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

January 10, 2024 | finance.yahoo.com

Mirati Therapeutics Inc [MRTX] Stock sold by Insider Christensen Jamie for $0.14 million

January 2, 2024 | knoxdaily.comK

Evaluating Mirati Therapeutics' CVR Value In The Wake Of The Bristol Myers Acquisition

December 25, 2023 | seekingalpha.com

Bristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 bln

December 22, 2023 | reuters.com

Media Sentiment Over Time

FGEN, HCM, and MRTX Company Descriptions

FibroGen NASDAQ:FGEN

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

HUTCHMED NASDAQ:HCM

$13.57 -0.31 (-2.23%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$13.60 +0.04 (+0.26%)

As of 04:03 AM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Mirati Therapeutics NASDAQ:MRTX

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FGEN, HCM, and MRTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FGEN, HCM, and MRTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FGEN, HCM, and MRTX Headlines

Recent News About These Companies

Media Sentiment Over Time

FGEN, HCM, and MRTX Company Descriptions

FibroGen NASDAQ:FGEN

HUTCHMED NASDAQ:HCM

Mirati Therapeutics NASDAQ:MRTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FGEN, HCM, and MRTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FGEN, HCM, and MRTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FGEN, HCM, and MRTX Headlines

Recent News About These Companies

Media Sentiment Over Time

FGEN, HCM, and MRTX Company Descriptions

FibroGen NASDAQ:FGEN

HUTCHMED NASDAQ:HCM

Mirati Therapeutics NASDAQ:MRTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools